CD274 and diffuse large B-cell lymphoma: Here, we outline most promising highlights in using immunotherapy against DLBCL, with a special focus on those that directly target the PD-1/PD-L1 axis or might indirectly cooperate with this therapeutic blockade through combination (Figure 3).